Organ systems

Global $5.3 Bn Cannabidiol (CBD) Oil Market to 2025

Friday, September 18, 2020 - 7:15pm

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Global Cannabidiol (CBD) Oil Industry Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 18, 2020 /PRNewswire/ -- The "Global Cannabidiol (CBD) Oil Industry Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • The global market for cannabidiol (CBD) oil should grow from $967.2 million in 2020 to $5.3 billion by 2025, at compound annual growth rate (CAGR) of 40.4% for the period of 2020-2025.
  • This study will enable readers to understand and gain insights into the current market and will forecast changing market scenarios.
  • The CBD oil market is a highly competitive market with the presence of many national, regional and local companies.

United States Scleroderma Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com

Friday, September 18, 2020 - 4:36pm

The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Scleroderma Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • US Scleroderma Market and Competitive Landscape Highlights - 2020, provides comprehensive insights into Scleroderma pipeline products, Scleroderma epidemiology, Scleroderma market valuations and forecast, Scleroderma drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Scleroderma treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2016 and forecast to 2025
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Scleroderma products

Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer

Friday, September 18, 2020 - 12:30pm

The oral presentation is entitled Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent.

Key Points: 
  • The oral presentation is entitled Phase 1b/2 study of VERU-111, novel, oral tubulin inhibitor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen blocking agent.
  • Based on these promising clinical data, VERU met with FDA on the Phase 3 clinical trial design in July 2020.
  • Veru Inc. is an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer.
  • VERU-111 is being evaluated in an open label Phase 1b/2 clinical study in men with metastatic castration and androgen receptor targeting agent resistant prostate cancer.

Worldwide Biguanide Industry to 2026 - by Segments and Geography - ResearchAndMarkets.com

Friday, September 18, 2020 - 12:13pm

The global biguanide market is forecast to grow at a CAGR of more than 7% rate during the forecast period 2020-2026.

Key Points: 
  • The global biguanide market is forecast to grow at a CAGR of more than 7% rate during the forecast period 2020-2026.
  • Till now, Metformin is the most common biguanide available in the global market for the management of type 2 diabetes.
  • Rise in the global incidence of type 2 diabetes is the major factor for the increase in demand for the biguanide during the forecast period.
  • In addition, the low cost of the drug, increasing the diagnosis rate of type 2 diabetes, increasing healthcare expenditure is also augmenting the biguanide market.

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months

Friday, September 18, 2020 - 6:00am

Post-hoc subgroup analysis in the pancreatic NETs cohort showed median PFS of 8.0 months (95% CI: 5.68.3) in patients with Ki67 10% (n=43).

Key Points: 
  • Post-hoc subgroup analysis in the pancreatic NETs cohort showed median PFS of 8.0 months (95% CI: 5.68.3) in patients with Ki67 10% (n=43).
  • The most common (10%) classes of TRAEs were gastrointestinal disorders (pancreatic NETs, 25.0%; midgut NETs, 37.3%) and general disorders/administration-site conditions (midgut NETs, 13.7%).
  • Together, these efficacy and safety results may represent an important therapeutic approach for patients living with pancreatic or midgut NETs.
  • Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results.

American Diabetes Association® Empowers Youth at Home Nationwide through Project Power

Thursday, September 17, 2020 - 10:05pm

ADA's Project Power, formerly known as Power Up, connects and empowers youth to make healthy lifestyle choices to develop lifelong habits and encourages youth to develop sustainable healthy household habits.

Key Points: 
  • ADA's Project Power, formerly known as Power Up, connects and empowers youth to make healthy lifestyle choices to develop lifelong habits and encourages youth to develop sustainable healthy household habits.
  • Youth participants will receive a special ADA Project Power Box and Activity Journal delivered to their homes.
  • The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive.
  • Join the fight with us on Facebook (American Diabetes Association ), Twitter ( @AmDiabetesAssn ) and Instagram ( @AmDiabetesAssn ).

United Spinal Plays Key Role In Passage Of Resolution Designating September 2020 As Spinal Cord Injury Awareness Month

Thursday, September 17, 2020 - 8:44pm

NEW YORK, Sept. 17, 2020 /PRNewswire/ -- United Spinal Association was instrumental in championing a resolution that passed the U.S. Senate designating September 2020 as National Spinal Cord Injury Awareness Month.

Key Points: 
  • NEW YORK, Sept. 17, 2020 /PRNewswire/ -- United Spinal Association was instrumental in championing a resolution that passed the U.S. Senate designating September 2020 as National Spinal Cord Injury Awareness Month.
  • We are grateful for their support," said James Weisman, president and CEO of United Spinal Association.
  • "United Spinal looks forward to working with both senators and all of Congress to address the issues impacting our community," added Weisman.
  • People who sustain a spinal cord injury often have permanent and profound neurologic deficits and accompanying disability.

Zynerba Pharmaceuticals Receives Orphan Drug Designation for Cannabidiol for the Treatment of 22q11.2 Deletion Syndrome

Thursday, September 17, 2020 - 6:55pm

DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q).

Key Points: 
  • DEVON, Pa., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration has granted orphan drug designation for cannabidiol (CBD) for use in treating 22q11.2 deletion syndrome (22q).
  • We are pleased that the FDA shares our sense of urgency regarding the development of effective therapeutics in this important patient population.
  • Under the Orphan Drug Act (ODA), the FDA may grant orphan drug designation to drugs intended to treat rare diseases or conditions that affect fewer than 200,000 individuals in the U.S.
  • As the second most common chromosomal disorder after Down syndrome, 22q is caused by a small missing piece of the 22nd chromosome.

CBD Validator Announces Key Milestones of Growth and Expansion - New Enhanced Rating System and the Largest Independent Database of Rated CBD Oil Products

Thursday, September 17, 2020 - 4:00pm

One new feature to the rating system includes the designation of ISO 17025 accredited for a testing laboratory in the evaluation.

Key Points: 
  • One new feature to the rating system includes the designation of ISO 17025 accredited for a testing laboratory in the evaluation.
  • CBD Validator's new rating system for pricing is based on a tiered analysis of its database of over 2,000 CBD oil products.
  • Each product receives a CBD Validator Score based on how it meets key criteria outlined in the proprietary 50-point rating system .
  • CBD Validator is a completely independent resource, not sponsored by any manufacturer of CBD products, and does not accept advertising or receive sales commissions from any manufacturers or marketers of CBD products.

Global Alpha Antitrypsin Deficiency (AATD) Market Analysis and Forecasts 2020-2030

Thursday, September 17, 2020 - 1:30pm

DUBLIN, Sept. 17, 2020 /PRNewswire/ -- The "Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 17, 2020 /PRNewswire/ -- The "Alpha Antitrypsin Deficiency (AATD)- Market Insights, Epidemiology and Market Forecast-2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Alpha Antitrypsin Deficiency (AATD) from 2017 to 2030 segmented by seven major markets.
  • The Alpha Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
  • It also provides treatment algorithms and treatment guidelines for Alpha Antitrypsin Deficiency in the US and Europe.